Ares Life to sell Esaote. Rotschild is the mandated advisor

Ares Life to sell Esaote. Rotschild is the mandated advisor
[caption id="attachment_502549" align="alignleft" width="402"] How Esaote's shareholders changed. Source: a presentation by former Esaote's chairman Carlo Castellano in 2010 (in 2014 Ares bought a 7.4% stake from Carige and a 0.8% from one of the managers)[/caption] Seven years after having acquired a major stake in Italy's Esaote, one of the world’s leading manufacturer of medical diagnostic systems, Ares Life Sciences is preparing to divest, DealReporter wrote. Rothschild is said to be the mandated advisor for the sale and the preferred option is listing the company on a Stock Exchange. Enterprise value is said to be about 400 million euros. Ares Life Sciences, a private equity fund focused on scientific and medical sectors owned by Ernesto Bertarelli, acquired a 39.2% stake in November 2009 in a deal that valued the company 280 million euros and that consisted in the reorganization of the company's shareholders stakes with the previous shareholders who lowered their stakes as follows: Intesa Sanpaolo bank to 19.2%, Equinox Two fund and Mps Venture 2 fund to 13.2% each and Banca Carige to 8.2%, while the management retained the remaining stake (see here the press release). In July 2014 Carige banks sold a 7.4% stake to Ares Life per a 17 million euros price, retaining a 0.77 (see here the press release) while one of the managers sold Ares its 0.8% stake so the fund raised its stake in Esaote to 48% (see Reuters). Chaired by Paolo Monfe[...]

Lascia un Commento

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *

È possibile utilizzare questi tag ed attributi XHTML: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>